Hydrochloric Acid

Hydrochloric Acid

SCHEMBL8335181

Cl.O=C(C1COc2ccccc2O1)N1CCNCC1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA known ✓ P10253 3/20 0.63
ALDH1A1 P00352 5/20 0.74
HPGD P15428 3/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
KMT2A Q03164 5/20 0.64
MAPK1 P28482 2/20 0.62
THRB P10828 1/20 0.61
POLB P06746 3/20 0.60
NPC1 O15118 2/20 0.60
TDP1 Q9NUW8 3/20 0.58
L3MBTL1 Q9Y468 2/20 0.55
ALOX15 P16050 1/20 0.55
HTT P42858 1/20 0.55
RECQL P46063 1/20 0.55
RAB9A P51151 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TSHR P16473 1/20 0.55
AIMP2 Q13155 1/20 0.54
MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31235619 1.00 ALDH1A1 (0.74) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL610143 0.99 ALDH1A1 (0.76) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL11483389 0.93 ALDH1A1 (0.78) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL13916514 0.86 ALDH1A1 (0.62) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL10167539 0.84 ALDH1A1 (0.97) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL4136572 0.83 ALDH1A1 (0.78) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL13916512 0.82 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL13202892 0.82 ALDH1A1 (0.76) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL3126859 0.82 ALDH1A1 (0.76) ALDH1A1HPGDSMN1; SMN2KMT2AGAA
SCHEMBL12593464 0.81 ALDH1A1 (0.74) ALDH1A1HPGDSMN1; SMN2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5919931-A Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines BRANTFORD CHEMICALS INC. (CA) 1999-07-06 US claimed
CN-102321080-B Doxazosin mesylate V form crystal, and preparation method and usage thereof NCPC NEW DRUG RES & DEV CO LTD 2013-09-25 CN disclosed
CN-102260250-B (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof NCPC NEW DRUG RES & DEV CO LTD 2013-09-25 CN disclosed
CN-102321078-B Doxazosin mesylate III form crystal, and preparation method and usage thereof NCPC NEW DRUG RES & DEV CO LTD 2013-08-28 CN disclosed
CN-102321079-B (-) doxazosin mesylate crystal VI as well as preparation method and application thereof NCPC NEW DRUG RES & DEV CO LTD 2013-08-28 CN disclosed
CN-102321078-A Doxazosin mesylate III form crystal, and preparation method and usage thereof NCPC NEW DRUG RES & DEV CO LTD 2012-01-18 CN disclosed
CN-102321080-A Doxazosin mesylate V form crystal, and preparation method and usage thereof NCPC NEW DRUG RES & DEV CO LTD 2012-01-18 CN disclosed
CN-102321079-A (-) doxazosin mesylate crystal VI as well as preparation method and application thereof NCPC NEW DRUG RES & DEV CO LTD 2012-01-18 CN disclosed
CN-102260249-A (-) doxazosin mesylate type II crystal as well as preparation method and application thereof 2011-11-30 CN disclosed
CN-102260250-A (-) doxazosin mesylate type IV crystal as well as preparation method and application thereof 2011-11-30 CN disclosed
CN-100999519-A Doxazosin mesylate, preparation method and application thereof NEW MEDICINE RES DEV CO LTD HU (CN) 2007-07-18 CN disclosed
CN-1769285-A Doxazosin salt with optical activity NCPC NEW DRUG RES AND DEV CO L (CN) 2006-05-10 CN disclosed
CN-1746168-A Optically active doxazosin salt HUABEI PHARMACEUTICAL GROUP NE (CN) 2006-03-15 CN disclosed
US-5919931-A Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines BRANTFORD CHEMICALS INC. (CA) 1999-07-06 US disclosed
EP-0028473-B1 CHLORO- AND ALKOXY-SUBSTITUTED-2,4-DIAMINOQUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER INC. (US) 1985-01-09 EP disclosed
US-4377581-A ANTIHYPERTENSIVE AGENTS PFIZER INC. (US) 1983-03-22 US disclosed
US-4351940-A Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines PFIZER INC. (US) 1982-09-28 US disclosed
US-4287341-A USEFUL AS ANTIHYPERTENSIVE AGENTS PFIZER INC. (US) 1981-09-01 US disclosed
EP-0028473-A1 Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them PFIZER INC. (US) 1981-05-13 EP disclosed
US-4188390-A Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines PFIZER INC. (US) 1980-02-12 US disclosed